Abstract
Albumin nanoparticles have become an attractive cancer nanomedicine platform due to their pharmaceutical advantages. Recently, photothermal therapy has been extensively applied to cancer treatment due to heat-induced tumor ablation. Herein, we fabricated albumin nanoparticles (HSA-NPs) loaded with paclitaxel (PTX), indocyanine green (ICG; a hyperthermal agent) and hyaluronidase (HAase) that breaks down hyaluronan, a major component of the extracellular matrix (ECM) in tumors. Synthesis was based on a slightly modified nanoparticle albumin-bound (Nab™) technique. The prepared nanoparticles (PTX/ICG/HAase-HSA-NPs) had a spherical shape with an average size of ~ 110 nm and a zeta potential of ~ -30.4 mV. They displayed good colloidal stability and typical patterns of ICG, HSA and HAase in UV–VIS–NIR and circular dichroism spectroscopic analysis. PTX/ICG/HAase-HSA-NPs were found to have excellent hyperthermal effects in response to near-infrared laser irradiation (808 nm) (up to > 50 °C over 4 min). The hyperthermia conducted by PTX/ICG/HAase-HSA-NPs resulted in significant cytotoxicity to pancreatic AsPC-1 cells at both severe (> 50 °C) and mild (41–42 °C) hyperthermal states in conjunction with the inherent cytotoxic activity of paclitaxel. Furthermore, the confocal images of AsPC-1 cell spheroids proved PTX/ICG/HAase-HSA-NPs were able to permeate deeply into the three-dimensional tumor tissue mimicry structure. Most of all, PTX/ICG/HAase-HSA-NPs maintained all these physicochemical and anti-cancer properties irrespective of the amount of embedded HAase (1–5 mg). Our results demonstrated that PTX/ICG/HAase-HSA-NPs are a promising hyperthermal/chemotherapeutic anticancer agent.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arpagaus C (2019) PLA/PLGA nanoparticles prepared by nano spray drying. J Pharm Invest 49:405–426. https://doi.org/10.1007/s40005-019-00460-0
Asadujjaman M, Cho KH, Jang DJ, Kim JE, Jee JP (2020) Nanotechnology in the arena of cancer immunotherapy. Arch Pharm Res 43:58–79. https://doi.org/10.1007/s12272-020-01207-4
Avci P, Gupta A, Sadasivam M, Vecchio D, Pam Z, Pam N, Hamblin MR (2013) Low-level laser (light) therapy (LLLT) in skin: stimulating, healing, restoring. Semin Cutan Med Surg 32:41–52
Bae S, Ma K, Kim TH, Lee ES, Oh KT, Park E-S, Lee KC, Youn YS (2012) Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33:1536–1546. https://doi.org/10.1016/j.biomaterials.2011.10.050
Byeon HJ, Lee S, Min SY, Lee ES, Shin BS, Choi H-G, Youn YS (2016) Doxorubicin-loaded nanoparticles consisted of cationic-and mannose-modified-albumins for dual-targeting in brain tumors. J Control Release 225:301–313. https://doi.org/10.1016/j.jconrel.2016.01.046
Choi SH, Byeon HJ, Choi JS, Thao L, Kim I, Lee ES, Shin BS, Lee KC, Youn YS (2015) Inhalable self-assembled albumin nanoparticles for treating drug-resistant lung cancer. J Control Release 197:199–207. https://doi.org/10.1016/j.jconrel.2014.11.008
Dai Phung C, Tran TH, Kim JO (2020) Engineered nanoparticles to enhance natural killer cell activity towards onco-immunotherapy: a review. Arch Pharm Res 43:32–45. https://doi.org/10.1007/s12272-020-01218-1
Desmettre T, Devoisselle J, Mordon S (2000) Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography. Surv Ophthalmol 45:15–27. https://doi.org/10.1016/S0039-6257(00)00123-5
Eble JA, Niland S (2019) The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis 36:171–198. https://doi.org/10.1007/s10585-019-09966-1
Elzoghby AO, Samy WM, Elgindy NA (2012) Albumin-based nanoparticles as potential controlled release drug delivery systems. J Control Release 157:168–182. https://doi.org/10.1016/j.jconrel.2011.07.031
Hill TK, Abdulahad A, Kelkar SS, Marini FC, Long TE, Provenzale JM, Mohs AM (2015) Indocyanine green-loaded nanoparticles for image-guided tumor surgery. Bioconjug Chem 26:294–303. https://doi.org/10.1021/bc5005679
Huang X, Brazel C (2001) On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J Control Release 73:121–136. https://doi.org/10.1016/S0168-3659(01)00248-6
Jaque D, Maestro LM, Del Rosal B, Haro-Gonzalez P, Benayas A, Plaza J, Rodriguez EM, Sole JG (2014) Nanoparticles for photothermal therapies. Nanoscale 6:9494–9530. https://doi.org/10.1039/C4NR00708E
Jo MJ, Jin IS, Park C-W, Hwang BY, Chung YB, Kim J-S, Shin DH (2020) Revolutionizing technologies of nanomicelles for combinatorial anticancer drug delivery. Arch Pharm Res 43:100–109. https://doi.org/10.1007/s12272-020-01215-4
Kang C, Kim D (2020) Nanoconfinement-mediated cancer theranostics. Arch Pharm Res 43:110–117. https://doi.org/10.1007/s12272-020-01217-2
Kang JK, Kim JC, Shin Y, Han SM, Won WR, Her J, Park JY, Oh KT (2020) Principles and applications of nanomaterial-based hyperthermia in cancer therapy. Arch Pharm Res 43:46–57. https://doi.org/10.1007/s12272-020-01206-5
Kim B, Seo B, Park S, Lee C, Kim JO, Oh KT, Lee ES, Choi H-G, Youn YS (2017) Albumin nanoparticles with synergistic antitumor efficacy against metastatic lung cancers. Colloids Surf B Biointerfaces 158:157–166. https://doi.org/10.1016/j.colsurfb.2017.06.039
Kim J, Jo Y-U, Na K (2020) Photodynamic therapy with smart nanomedicine. Arch Pharm Res 43:22–31. https://doi.org/10.1007/s12272-020-01214-5
Kratz F (2008) Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171–183. https://doi.org/10.1016/j.jconrel.2008.05.010
Kratz F (2014) A clinical update of using albumin as a drug vehicle—a commentary. J Control Release 190:331–336. https://doi.org/10.1016/j.jconrel.2014.03.013
Lamichhane S, Lee S (2020) Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy. Arch Pharm Res 43:118–133. https://doi.org/10.1007/s12272-020-01204-7
Le XT, Youn YS (2020) Emerging NIR light-responsive delivery systems based on lanthanide-doped upconverting nanoparticles. Arch Pharm Res 43:134–152. https://doi.org/10.1007/s12272-020-01208-3
Lee ES, Youn YS (2016) Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation. J Pharm Investig 46:305–315. https://doi.org/10.1007/s40005-016-0250-3
Lee C, Kim B, Lee S, Kim TH, Kim JO, Lee ES, Oh KT, Choi H-G, Yoo SD, Youn YS (2017) Doxorubicin and paclitaxel co-bound lactosylated albumin nanoparticles having targetability to hepatocellular carcinoma. Colloids Surf B 152:183–191. https://doi.org/10.1016/j.colsurfb.2017.01.017
Lee GH, Shin DH, Suh H-W, Lee J-Y, Lim SS, Kim J-S (2019) Liposomal formulation and pharmacokinetic study of CPD409, a novel sodium channel blocker. J Pharm Invest 49:565–573. https://doi.org/10.1007/s40005-019-00445-z
Lohcharoenkal W, Wang L, Chen YC, Rojanasakul Y (2014) Protein nanoparticles as drug delivery carriers for cancer therapy. BioMed Res Int 2014:1–12. https://doi.org/10.1155/2014/180549
Min SY, Byeon HJ, Lee C, Seo J, Lee ES, Shin BS, Choi H-G, Lee KC, Youn YS (2015) Facile one-pot formulation of TRAIL-embedded paclitaxel-bound albumin nanoparticles for the treatment of pancreatic cancer. Int J Pharm 494:506–515. https://doi.org/10.1016/j.ijpharm.2015.08.055
Mundra V, Peng Y, Rana S, Natarajan A, Mahato RI (2015) Micellar formulation of indocyanine green for phototherapy of melanoma. J Control Release 220:130–140. https://doi.org/10.1016/j.jconrel.2015.10.029
Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, Bollyky PL (2015) 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol 6:123. https://doi.org/10.3389/fimmu.2015.00123
Park S, Kim H, Lim SC, Lim K, Lee ES, Oh KT, Choi H-G, Youn YS (2019) Gold nanocluster-loaded hybrid albumin nanoparticles with fluorescence-based optical visualization and photothermal conversion for tumor detection/ablation. J Control Release 304:7–18. https://doi.org/10.1016/j.jconrel.2019.04.036
Phuong PTT, Lee S, Lee C, Seo B, Park S, Oh KT, Lee ES, Choi H-G, Shin BS, Youn YS (2018) Beta-carotene-bound albumin nanoparticles modified with chlorin e6 for breast tumor ablation based on photodynamic therapy. Colloids Surf B 171:123–133. https://doi.org/10.1016/j.colsurfb.2018.07.016
Prabhakar U, Maeda H, Jain RK, Sevick-Muraca EM, Zamboni W, Farokhzad OC, Barry ST, Gabizon A, Grodzinski P, Blakey DC (2013) Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology. Cancer Res 73:2412–2417. https://doi.org/10.1158/0008-5472.CAN-12-4561
Seo B, Lim K, Kim SS, Oh KT, Lee ES, Choi H-G, Shin BS, Youn YS (2019) Small gold nanorods-loaded hybrid albumin nanoparticles with high photothermal efficacy for tumor ablation. Colloids Surf B 179:340–351. https://doi.org/10.1016/j.colsurfb.2019.03.068
Sheng Z, Hu D, Zheng M, Zhao P, Liu H, Gao D, Gong P, Gao G, Zhang P, Ma Y (2014) Smart human serum albumin-indocyanine green nanoparticles generated by programmed assembly for dual-modal imaging-guided cancer synergistic phototherapy. ACS Nano 8:12310–12322. https://doi.org/10.1021/nn5062386
Shimizu S, Kamiike W, Hatanaka N, Yoshida Y, Tagawa K, Miyata M, Matsuda H (1995) New method for measuring ICG Rmax with a clearance meter. World J Surg 19:113–118
Sordillo LA, Pu Y, Pratavieira S, Budansky Y, Alfano RR (2014) Deep optical imaging of tissue using the second and third near-infrared spectral windows. J Biomed Opt 19:056004. https://doi.org/10.1117/1.JBO.19.5.056004
Styles IK, Feeney OM, Nguyen TH, Brundel DHS, Kang DW, Clift R, Mcintosh MP, Porter CJH (2019) Removal of interstitial hyaluronan with recombinant human hyaluronidase improves the systemic and lymphatic uptake of cetuximab in rats. J Control Release 315:85–96. https://doi.org/10.1016/j.jconrel.2019.10.040
Thao LQ, Byeon HJ, Lee C, Lee S, Lee ES, Choi YW, Choi H-G, Park E-S, Lee KC, Youn YS (2016) Doxorubicin-bound albumin nanoparticles containing a TRAIL protein for targeted treatment of colon cancer. Pharm Res 33:615–626. https://doi.org/10.1007/s11095-015-1814-z
Toole B (1973) Hyaluronate and hyaluronidase in morphogenesis and differentiation. Amer Jool 13:1061–1065. https://doi.org/10.1093/icb/13.4.106
Tran P, Lee S-E, Kim D-H, Pyo Y-C, Park J-S (2019) Recent advances of nanotechnology for the delivery of anticancer drugs for breast cancer treatment. J Pharm Invest 50:261–270. https://doi.org/10.1007/s40005-019-00459-7
Whatcott CJ, Han H, Posner RG, Hostetter G, Von Hoff DD (2011) Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look. Cancer Discov 1:291–296. https://doi.org/10.1158/2159-8290.CD-11-0136
Youn YS, Bae YH (2018) Perspectives on the past, present, and future of cancer nanomedicine. Adv Drug Deliv Rev 130:3–11. https://doi.org/10.1016/j.addr.2018.05.008
Yuan B, Chen N, Zhu Q (2004) Emission and absorption properties of indocyanine green in Intralipid solution. J Biomed Opt 9:497–504. https://doi.org/10.1117/1.1695411
Acknowledgements
This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government (MSIT) (No. NRF-2019R1A5A2027340), and a grant (16173MFDS542) from the Ministry of Food and Drug Safety in 2020.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Kim, S.S., Kim, H.K., Kim, H. et al. Hyperthermal paclitaxel-bound albumin nanoparticles co-loaded with indocyanine green and hyaluronidase for treating pancreatic cancers. Arch. Pharm. Res. 44, 182–193 (2021). https://doi.org/10.1007/s12272-020-01264-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12272-020-01264-9